Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Medtronic
Moodys
Merck
QuintilesIMS
Daiichi Sankyo
Baxter
Federal Trade Commission

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,333,204

« Back to Dashboard

Which drugs does patent 9,333,204 protect, and when does it expire?

Patent 9,333,204 protects VIEKIRA XR and is included in one NDA.

This patent has three patent family members in three countries.
Summary for Patent: 9,333,204
Title:Solid antiviral dosage forms
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
Inventor(s): Miller; Jonathan M. (Lindenhurst, ID), Morris; John B. (Grayslake, IL), Sever; Nancy E. (Northbrook, IL), Schmitt; Eric A. (Libertyville, IL), Gao; Ping X. (Highland Park, IL), Shi; Yi (Libertyville, IL), Gao; Yi (Vernon Hills, IL), Liepold; Bernd (Dossenheim, DE), Moosmann; Anna (Winterbach, DE), Pauli; Mirko (Ludwigshafen, DE), Durak; Fatih (Ludwigshafen, DE), Kessler; Thomas (Schifferstadt, DE), Hoelig; Peter A. (Waechtersbach, DE), Rosenblatt; Karin (Mannheim, DE), Kostelac; Drazen (Mannheim, DE), Gokhale; Rajeev (Singapore, SG), Costello; Mark (Chicago, IL), Knable; Carl (Elmhurst, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:14/677,611
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 9,333,204

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,333,204

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,744,170 Solid antiviral dosage forms ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,333,204

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3089757 ➤ Try a Free Trial
Taiwan 201609195 ➤ Try a Free Trial
World Intellectual Property Organization (WIPO) 2015103490 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
Argus Health
AstraZeneca
Chubb
US Army
Express Scripts
Accenture
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.